Report Information More information from: https ://www.wis eguyreports .com/reports /495876
Rubella - Pipeline Review, H1 2016 Report / Search Code: WGR495876
Price
1-user P DF : $ 2000.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 4000.0
Enterprise P DF : $ 6000.0
Rubella - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Rubella - Pipeline Review, H1 2016’, provides an overview of the Rubella pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Rubella, complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for Rubella and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of Rubella - The report reviews pipeline therapeutics for Rubella by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved Rubella therapeutics and enlis ts all their major and minor projects - The report as s es s es Rubella therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for Rubella Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Rubella - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Rubella pipeline depth and focus of Indication therapeutics
- Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:
Table of Contents Table of Contents 2 Lis t of Tables 4 Lis t of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Rubella Overview 6 Therapeutics Development 7 Pipeline Products for Rubella - Overview 7 Pipeline Products for Rubella - Comparative Analys is 8 Rubella - Therapeutics under Development by Companies 9 Rubella - Therapeutics under Inves tigation by Univers ities /Ins titutes 10 Rubella - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Rubella - Products under Development by Companies 14 Rubella - Products under Inves tigation by Univers ities /Ins titutes 15 Rubella - Companies Involved in Therapeutics Development 16 Beijing Minhai Biotechnology Co., Ltd 16 Beijing Tiantan Biological Products Co., Ltd. 17 Biological E. Limited 18 China National Pharmaceutical Group Corporation 19 Daiichi Sankyo Company, Limited 20 GlaxoSmithKline Plc 21 Prometheon Pharma, LLC 22 Sinovac Biotech Ltd. 23 Z ydus Cadila Healthcare Limited 24 Rubella - Therapeutics As s es s ment 25 As s es s ment by Monotherapy Products 25 As s es s ment by Combination Products 26 As s es s ment by Route of Adminis tration 27 As s es s ment by Molecule Type 29 Drug Profiles 31 (meas les + mumps + rubella + varicella) (tetravalent) vaccine - Drug Profile 31 Product Des cription 31 Mechanis m of Action 31 R& D Progres s 31 (meas les + mumps + rubella + varicella) vaccine - Drug Profile 32 Product Des cription 32 Mechanis m of Action 32 R& D Progres s 32 (meas les + mumps + rubella) vaccine - Drug Profile 33 Product Des cription 33 Mechanis m of Action 33 R& D Progres s 33 (meas les + mumps + rubella) vaccine - Drug Profile 34 Product Des cription 34 Mechanis m of Action 34 R& D Progres s 34 (meas les + mumps + rubella) vaccine - Drug Profile 35 Product Des cription 35 Mechanis m of Action 35 R& D Progres s 35 (meas les + rubella + varicella) vaccine - Drug Profile 36 Product Des cription 36 Mechanis m of Action 36 R& D Progres s 36 (meas les + rubella) vaccine - Drug Profile 37 Product Des cription 37 Mechanis m of Action 37 R& D Progres s 37 (meas les + rubella) vaccine - Drug Profile 38 Product Des cription 38 Mechanis m of Action 38 R& D Progres s 38 (meas les [s train Schwarz] + mumps [s train RIT 4385] + rubella [s train Wis tar RA 27/3]) vaccine - Drug Profile 39 Product Des cription 39 Mechanis m of Action 39 R& D Progres s 39
meas les + mumps + rubella + varicella vaccine - Drug ProďŹ le 40 Product Des cription 40 Mechanis m of Action 40 R& D Progres s 40 VN-0102 - Drug ProďŹ le 41 Product Des cription 41 Mechanis m of Action 41 R& D Progres s 41 Rubella - Recent Pipeline Updates 42 Rubella - Dormant Projects 43 Appendix 44 Methodology 44 Coverage 44 Secondary Res earch 44 Primary Res earch 44 Expert Panel Validation 44 Contact Us 44 Dis claimer 45 Lis t of Tables Number of Products under Development for Rubella, H1 2016 7 Number of Products under Development for Rubella - Comparative Analys is , H1 2016 8 Number of Products under Development by Companies , H1 2016 9 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 10 Comparative Analys is by Late Stage Development, H1 2016 11 Comparative Analys is by Clinical Stage Development, H1 2016 12 Comparative Analys is by Early Stage Development, H1 2016 13 Products under Development by Companies , H1 2016 14 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 15 Rubella - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 16 Rubella - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2016 17 Rubella - Pipeline by Biological E. Limited, H1 2016 18 Rubella - Pipeline by China National Pharmaceutical Group Corporation, H1 2016 19 Rubella - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 20 Rubella - Pipeline by GlaxoSmithKline Plc, H1 2016 21 Rubella - Pipeline by Prometheon Pharma, LLC, H1 2016 22 Rubella - Pipeline by Sinovac Biotech Ltd., H1 2016 23 Rubella - Pipeline by Z ydus Cadila Healthcare Limited, H1 2016 24 As s es s ment by Monotherapy Products , H1 2016 25 As s es s ment by Combination Products , H1 2016 26 Number of Products by Stage and Route of Adminis tration, H1 2016 28 Number of Products by Stage and Molecule Type, H1 2016 30 Rubella Therapeutics - Recent Pipeline Updates , H1 2016 42 Rubella - Dormant Projects , H1 2016 43 Lis t of Figures Number of Products under Development for Rubella, H1 2016 7 Number of Products under Development for Rubella - Comparative Analys is , H1 2016 8 Number of Products under Development by Companies , H1 2016 9 Comparative Analys is by Clinical Stage Development, H1 2016 12 Comparative Analys is by Early Stage Products , H1 2016 13 As s es s ment by Combination Products , H1 2016 26 Number of Products by Routes of Adminis tration, H1 2016 27 Number of Products by Stage and Routes of Adminis tration, H1 2016 27 Number of Products by Molecule Types , H1 2016 29 Number of Products by Stage and Molecule Types , H1 2016 29
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349